Search clinical trials for: glembatumumab vedotin

Total 391 results

Masonic Cancer Center, University of Minnesota

Terminated

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Germ Cell Tumor

United States
Canadian Cancer Trials Group
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

Canada
Kyoto University Hospital
Merck Sharp & Dohme LLC; Astellas Pharma Inc; University of Tsukuba; Kobe City... and other collaborators

Recruiting

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

Bladder Cancer

Japan
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

United States, Canada, Belgium, Spain, United Kingdom
Seagen Inc.
Genmab

Recruiting

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301)

Cervical Cancer

United States, Canada, Japan, Austria, Belgium, China, France, Korea, Republic of, Netherlands, Singapore, Spain, United Kingdom, Argentina, Brazil, Germany, Norway, Peru, Poland, Finland, Denmark, Ireland, Italy, Czechia, Hungary, Taiwan, Swed... and more
University of Washington
Genentech, Inc.

Recruiting

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone...

United States
Washington University School of Medicine

Recruiting

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Post-transplant Lymphoproliferative Disorder

United States
Astellas Pharma Global Development, Inc.
Seagen Inc.

Active, not recruiting

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Bladder Cancer | Urothelial Cancer | Ureteral Cancer

United States, Japan, Korea, Republic of, Taiwan, Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain, Switzerland, United Kingdom
Sun Yat-sen University

Recruiting

RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer (DETECT)

Colorectal Cancer

China
Beijing Children's Hospital

Enrolling by invitation

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Hodgkin Lymphoma

China
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Disease, Hodgkin

United States, Canada
Mirati Therapeutics Inc.

Terminated

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma Bladder | Urothelial Carcinoma | Urothelial Carcinoma Ureter | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Urethra

United States
Hull University Teaching Hospitals NHS Trust
Galen Limited

Withdrawn

Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
Hoffmann-La Roche

Completed

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse

United States, France, Spain, Italy
Takeda
Seagen Inc.

Active, not recruiting

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, France, Italy, Poland, United Kingdom, Belgium, Hong Kong, Taiwan, Spain, South Africa, Turkey, Canada, Denmark, Korea, Republic of, Australia, Russian Federation, Brazil, Hungary, Norway, Czechia, Japan
Columbia University

Completed

Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (SGN+Benda)

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma

Canada, United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Seagen Inc.

Active, not recruiting

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Peripheral T-cell Lymphoma

United States, Czechia, Italy, Spain, United Kingdom, France
Seagen Inc.
Bristol-Myers Squibb

Active, not recruiting

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, Australia, Czechia, Italy, Spain, Poland
University of Washington
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) (PENUT)

Extreme Prematurity

United States
Chunguang yang (101937)

Recruiting

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Urothelial Carcinoma | Radical Cystectomy

China
Lawson Health Research Institute
Seagen Inc.

Completed

Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis

Canada
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Not yet recruiting

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
University College, London
University of Miami; Takeda; European Organisation for Research and Treatment... and other collaborators

Recruiting

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR)

Hodgkin Lymphoma

United Kingdom, New Zealand, Australia, United States, Belgium, Spain
Seagen Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Neoplasms

United States, Spain, Korea, Republic of, Germany
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Diffuse, Large B-Cell, Lymphoma

China
M.D. Anderson Cancer Center

Recruiting

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Hodgkin Lymphoma | B-Cell Lymphoma | Relapsed B-cell NHL

United States
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)

Urothelial Cancer

United States, Argentina, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, Thailand and more
Mirati Therapeutics Inc.

Active, not recruiting

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Advanced or Metastatic Solid Malignancies

United States
Seagen Inc.
Merck Sharp & Dohme LLC

Terminated

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Melanoma | Small Cell Lung Cancer | Prostate Cancer | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma | Non-small Cell Lung Cancer, Squamous | Non-small Cell Lung Cancer, Non-squamous

United States, Korea, Republic of, Italy, United Kingdom, Australia, Taiwan
Hoffmann-La Roche

Completed

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

United States, Spain, Korea, Republic of, France, Austria, Poland
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center; Stanford University; University of Rochester; Seagen...

Active, not recruiting

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Hodgkin Lymphoma

United States
AbbVie

Not yet recruiting

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Non-Small Cell Lung Cancer
Hoffmann-La Roche

Recruiting

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO)

Non-Hodgkin Lymphoma

United States, Korea, Republic of, China, Mexico, Japan, Brazil, Argentina, Thailand, Canada, Peru, Turkey, Russian Federation, Israel, New Zealand
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (ECHELON-2)

Non-Hodgkin Lymphoma | T-Cell Lymphoma | Anaplastic Large-Cell Lymphoma

United States, Korea, Republic of, Spain, United Kingdom, Taiwan, Czechia, Hungary, France, Israel, Germany, Italy, Denmark, Australia, Poland, Romania, Canada
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Active, not recruiting

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Italy, Spain, Canada, France, Puerto Rico
Seagen Inc.

Terminated

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Follicular B-cell Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma Refractory

United States, Italy, Spain, United Kingdom, Czechia, Poland, France
Yale University

Withdrawn

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Hematopoietic/Lymphoid Cancer | Infectious Mononucleosis | PTLD | Lymphoid Tumor | Plasmacytic Hyperplasia PTLD | Florid Follicular Hyperplasia PTLD | Polymorphic PTLD | Monomorphic PTLD | Classical Hodgkin Lymphoma Type PTLD

United States
Shire

Completed

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

United States, Jordan, Canada
University of Arizona

Withdrawn

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (S-BR)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Mediastinal Large B-cell Lymphoma | Grey Zone Lymphoma | High Grade B Cell Lymphoma

United States
Seagen Inc.

Terminated

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Lymphoma, Large B-cell, Diffuse | Lymphoma, B-cell

United States, Spain, Italy, Czechia, Poland
Merck Sharp & Dohme LLC
Seagen Inc.; Astellas Pharma Global Development, Inc.

Active, not recruiting

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Urinary Bladder Cancer, Muscle-invasive

Canada, United States, Australia, Belgium, France, Hungary, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Thailand, Ukraine, Argentina, Colombia, Denmark, Germany, Ireland, Israel, Japan, Malaysia, Philippines, Sing... and more
The Lymphoma Academic Research Organisation

Completed

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma (AMC-085)

HIV Infection | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | HIV-associated Hodgkin Lymphoma

France
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Lymphoma, Large-Cell, Anaplastic | Lymphoma, NK-cell | Lymphoma, T-cell

United States, United Kingdom
Merck Sharp & Dohme LLC
Astellas Pharma Inc; Seagen Inc.

Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

Bladder Cancer

Hungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more
St Stephens Aids Trust
Gilead Sciences

Completed

SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms

HIV

United Kingdom
AbbVie

Active, not recruiting

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Advanced Solid Tumors Cancer

United States, Belgium, Finland, France, Italy, Japan, Korea, Republic of, Netherlands, Taiwan
Chinese PLA General Hospital

Not yet recruiting

Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.

PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma

Search clinical trials for: glembatumumab vedotin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations